Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Market Cap
$1.66B
P/E Ratio
-4.87
1Y Stock Return
17.45%
1Y Revenue Growth
-12.97%
Dividend Yield
0.00%
Price to Book
3.2
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MSDL | 0.01% | $1.89B | +4.09% | 7.02% |
CMG | -0.02% | $82.49B | +36.40% | 0.00% |
DAVE | 0.06% | $1.19B | +1,326.53% | 0.00% |
CCAP | -0.09% | - | - | 8.56% |
MPAA | 0.10% | $153.06M | -21.49% | 0.00% |
RSG | 0.11% | $67.32B | +32.23% | 1.02% |
STKL | -0.14% | $919.93M | +49.22% | 0.00% |
CYD | -0.18% | $384.89M | +1.29% | 4.07% |
GL | 0.19% | $9.24B | -11.66% | 0.85% |
XOS | 0.23% | $31.23M | -51.23% | 0.00% |
ALLY | -0.26% | $11.94B | +27.36% | 3.05% |
VIST | -0.28% | $5.07B | +77.15% | 0.00% |
STNG | -0.29% | $2.67B | -9.16% | 3.15% |
TKO | 0.36% | $10.95B | +78.74% | 0.00% |
CYCN | 0.42% | $6.34M | +3.08% | 0.00% |
HRTG | 0.43% | $379.26M | +33.62% | 0.00% |
UUU | -0.45% | $5.04M | 0.00% | 0.00% |
MAGN | -0.46% | $708.59M | -1.13% | 0.00% |
CHD | 0.49% | $27.25B | +16.97% | 1.02% |
MODV | -0.49% | $264.39M | -53.13% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACGL | -15.40% | $37.36B | +27.37% | 0.00% |
BTCT | -14.97% | $60.65M | +335.42% | 0.00% |
RNR | -13.48% | $14.93B | +37.70% | 0.54% |
MNOV | -12.84% | $116.73M | +36.78% | 0.00% |
PGR | -12.14% | $154.68B | +61.58% | 0.43% |
PRPO | -11.10% | $8.83M | -10.62% | 0.00% |
TEM | -10.62% | $9.91B | 0.00% | 0.00% |
TH | -10.57% | $800.43M | -25.92% | 0.00% |
PULM | -9.73% | $23.16M | +215.42% | 0.00% |
FATBB | -8.87% | $78.36M | -13.31% | 12.28% |
CI | -8.52% | $93.75B | +28.20% | 1.61% |
WHLM | -8.44% | $20.47M | -13.32% | 0.00% |
TPST | -8.15% | $41.52M | -71.85% | 0.00% |
NOC | -6.75% | $70.63B | +0.92% | 1.66% |
CME | -6.44% | $84.90B | +9.89% | 1.92% |
VIRT | -6.31% | $3.25B | +106.50% | 2.53% |
MCK | -5.60% | $78.87B | +35.27% | 0.43% |
BNED | -5.34% | $293.05M | -90.24% | 0.00% |
VNOM | -5.11% | $5.59B | +79.64% | 3.27% |
TXO | -5.04% | $720.48M | -4.86% | 13.59% |
Yahoo
Viridian Therapeutics ( NASDAQ:VRDN ) Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss widened...
Yahoo
WALTHAM, Mass., November 12, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ending September 30, 2024.
Finnhub
Corporate Presentation November 2024 Cautionary note regarding forward-looking statements This presentation contains...
Finnhub
WALTHAM - Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a...
Yahoo
WALTHAM, Mass., November 05, 2024--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 150,600 shares of the company’s common stock to
Yahoo
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALLO | 51.98% | $534.66M | -0.39% | 0.00% |
FATE | 47.53% | $337.13M | +16.54% | 0.00% |
TWST | 46.40% | $2.99B | +96.56% | 0.00% |
CRBU | 46.16% | $214.61M | -59.21% | 0.00% |
ABCL | 43.65% | $894.96M | -34.70% | 0.00% |
AVO | 42.45% | $952.33M | +47.58% | 0.00% |
ILMN | 41.92% | $23.02B | +30.29% | 0.00% |
KRNT | 41.85% | $1.51B | +69.47% | 0.00% |
VIR | 40.92% | $1.12B | -14.84% | 0.00% |
NTLA | 40.69% | $1.60B | -49.08% | 0.00% |
KROS | 40.50% | $2.30B | +78.23% | 0.00% |
EDIT | 39.10% | $180.78M | -80.18% | 0.00% |
MRSN | 38.98% | $284.13M | +12.75% | 0.00% |
YORW | 37.96% | $513.16M | -9.71% | 2.37% |
MGTX | 37.85% | $518.94M | +27.20% | 0.00% |
CTO | 37.57% | $605.82M | +15.88% | 7.51% |
ENTA | 37.44% | $181.64M | -14.30% | 0.00% |
PTGX | 37.44% | $2.58B | +137.17% | 0.00% |
ALEX | 37.41% | $1.42B | +11.81% | 4.53% |
ALEC | 37.18% | $245.81M | -55.34% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -37.60% | $365.42M | 1.43% |
USDU | -17.22% | $210.52M | 0.5% |
UUP | -17.18% | $376.91M | 0.77% |
VIXY | -15.71% | $195.31M | 0.85% |
DBA | -12.81% | $787.55M | 0.93% |
AGZD | -10.22% | $132.76M | 0.23% |
CTA | -9.45% | $367.83M | 0.76% |
DBO | -7.84% | $218.47M | 0.77% |
DBE | -7.66% | $50.22M | 0.77% |
EQLS | -6.24% | $8.93M | 1% |
SOYB | -6.04% | $27.06M | 0.22% |
KMLM | -4.76% | $344.74M | 0.9% |
FBY | -4.00% | $142.09M | 0.99% |
TBIL | -3.29% | $4.42B | 0.15% |
HDRO | -2.71% | $164.26M | 0.3% |
CLOI | -2.57% | $749.05M | 0.4% |
BILZ | -1.82% | $541.42M | 0.14% |
MINT | -1.33% | $11.69B | 0.35% |
USCI | -0.79% | $188.19M | 1.07% |
COMT | -0.52% | $839.86M | 0.48% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 53.72% | $7.29B | 0.35% |
GNOM | 52.13% | $79.38M | 0.5% |
IBB | 50.27% | $6.97B | 0.45% |
PBE | 50.13% | $263.25M | 0.58% |
ARKG | 49.97% | $1.27B | 0.75% |
FBT | 48.38% | $1.19B | 0.56% |
IWC | 46.66% | $996.57M | 0.6% |
XPH | 45.86% | $164.49M | 0.35% |
BBH | 44.29% | $421.45M | 0.35% |
PTH | 43.65% | $141.39M | 0.6% |
ARKK | 42.69% | $6.76B | 0.75% |
VTWO | 42.49% | $13.16B | 0.1% |
IWO | 42.23% | $13.37B | 0.24% |
IWM | 42.09% | $80.66B | 0.19% |
RIET | 41.93% | $92.01M | 0.5% |
SMDV | 41.85% | $777.07M | 0.4% |
EES | 41.78% | $696.65M | 0.38% |
DES | 41.25% | $2.21B | 0.38% |
IFRA | 41.06% | $3.40B | 0.3% |
KOMP | 40.99% | $2.22B | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
KRBN | -0.14% | $235.35M | 0.85% |
CORN | -0.15% | $59.94M | 0.2% |
GSG | -0.20% | $932.06M | 0.75% |
WEAT | -0.27% | $119.27M | 0.28% |
KCCA | -0.32% | $219.07M | 0.87% |
TAIL | 0.47% | $68.19M | 0.59% |
BIL | -0.51% | $34.29B | 0.1356% |
COMT | -0.52% | $839.86M | 0.48% |
USCI | -0.79% | $188.19M | 1.07% |
CANE | 1.05% | $16.65M | 0.29% |
PDBC | 1.12% | $4.39B | 0.59% |
MINT | -1.33% | $11.69B | 0.35% |
DBMF | 1.44% | $1.04B | 0.85% |
JBBB | 1.68% | $1.35B | 0.49% |
BILZ | -1.82% | $541.42M | 0.14% |
IBHD | 2.21% | $320.14M | 0.35% |
FTGC | 2.21% | $2.20B | 1.02% |
DBC | 2.27% | $1.39B | 0.87% |
MSOS | 2.55% | $603.47M | 0.83% |
CLOI | -2.57% | $749.05M | 0.4% |
Current Value
$21.001 Year Return
Current Value
$21.001 Year Return